Does Aggressive Variant Histology Without Invasive Features Predict Overall Survival in Papillary Thyroid Cancer?: A National Cancer Database Analysis.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
pubmed:
11
10
2019
medline:
24
9
2021
entrez:
11
10
2019
Statut:
ppublish
Résumé
We aimed to clarify whether aggressive histology of papillary thyroid cancer (PTC) impacts overall survival (OS). Aggressive variants of PTC (AVPTC) are associated with invasive features. However, their behavior in the absence of these features is not well characterized. Patients treated from 2004 to 2015 for classic PTC (cPTC) or AVPTCs were identified from the National Cancer Database. Patients were further stratified based on presence of at least 1 invasive feature-extrathyroidal extension, multifocality, lymphovascular invasion, nodal or distant metastasis. Demographics, treatments, and OS were compared. A total of 170,778 patients were included-162,827 cPTC and 7951 AVPTC. Invasive features were more prevalent in AVPTC lesions compared to cPTC (70.7% vs 59.7%, P < 0.001). AVPTC included tall cell/columnar cell (89.5%) and diffuse sclerosing (10.5%) variants. Patients with invasive features had worse OS irrespective of histology. Furthermore, when controlling for demographics, tumor size, and treatment variables in patients with noninvasive lesions, AVPTC histology alone was not associated with worse OS compared to cPTC (P = 0.209). In contrast, among patients who had at least 1 invasive feature, AVPTC histology was independently predictive of worse OS (P < 0.05) {TCV/Columnar hazard ratio [HR] 1.2; [95% confidence interval (CI) 1.1-1.3] and diffuse sclerosing HR 1.3; 95% CI 1.0-1.7]}. All invasive features, except multifocality, were independently associated with worse OS, with metastasis being the most predictive [HR 2.9 (95% CI 2.6-3.2) P < 0.001]. In the absence of invasive features, AVPTC histology has similar OS compared to cPTC. In contrast, diffuse sclerosing and tall cell/columnar variants are associated with worse OS when invasive features are present.
Sections du résumé
OBJECTIVE
We aimed to clarify whether aggressive histology of papillary thyroid cancer (PTC) impacts overall survival (OS).
SUMMARY BACKGROUND DATA
Aggressive variants of PTC (AVPTC) are associated with invasive features. However, their behavior in the absence of these features is not well characterized.
METHODS
Patients treated from 2004 to 2015 for classic PTC (cPTC) or AVPTCs were identified from the National Cancer Database. Patients were further stratified based on presence of at least 1 invasive feature-extrathyroidal extension, multifocality, lymphovascular invasion, nodal or distant metastasis. Demographics, treatments, and OS were compared.
RESULTS
A total of 170,778 patients were included-162,827 cPTC and 7951 AVPTC. Invasive features were more prevalent in AVPTC lesions compared to cPTC (70.7% vs 59.7%, P < 0.001). AVPTC included tall cell/columnar cell (89.5%) and diffuse sclerosing (10.5%) variants. Patients with invasive features had worse OS irrespective of histology. Furthermore, when controlling for demographics, tumor size, and treatment variables in patients with noninvasive lesions, AVPTC histology alone was not associated with worse OS compared to cPTC (P = 0.209). In contrast, among patients who had at least 1 invasive feature, AVPTC histology was independently predictive of worse OS (P < 0.05) {TCV/Columnar hazard ratio [HR] 1.2; [95% confidence interval (CI) 1.1-1.3] and diffuse sclerosing HR 1.3; 95% CI 1.0-1.7]}. All invasive features, except multifocality, were independently associated with worse OS, with metastasis being the most predictive [HR 2.9 (95% CI 2.6-3.2) P < 0.001].
CONCLUSIONS
In the absence of invasive features, AVPTC histology has similar OS compared to cPTC. In contrast, diffuse sclerosing and tall cell/columnar variants are associated with worse OS when invasive features are present.
Identifiants
pubmed: 31599802
pii: 00000658-202109000-00028
doi: 10.1097/SLA.0000000000003632
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e276-e281Informations de copyright
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
SEER ∗ Explorer Application [Internet]. [cited 2019 Apr 23]. Available at: https://seer.cancer.gov/explorer/application.php .
Michels JJ, Jacques M, Henry-Amar M, et al. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol 2007; 38:212–219.
Silver CE, Owen RP, Rodrigo JP, et al. Aggressive variants of papillary thyroid carcinoma. Head Neck 2011; 33:1052–1059.
Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol 2012; 19:1874–1880.
Song E, Jeon MJ, Oh H-S, et al. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma? Eur J Endocrinol 2018; 179:135–142.
Kim HJ, Sohn SY, Jang HW, et al. Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma. World J Surg 2013; 37:376–384.
Joseph KR, Edirimanne S, Eslick GD. Multifocality as a prognostic factor in thyroid cancer: A meta-analysis. Int J Surg 2018; 50:121–125.
Kim K-J, Kim S-M, Lee YS, et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2,309 consecutive patients. Ann Surg Oncol 2015; 22:125–131.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1–133.
Nath MC, Erickson LA. Aggressive variants of papillary thyroid carcinoma: hobnail, tall cell, columnar, and solid. Adv Anat Pathol 2018; 25:172–179.
Beninato T, Scognamiglio T, Kleiman DA, et al. Ten percent tall cells confer the aggressive features of the tall cell variant of papillary thyroid carcinoma. Surgery 2013; 154:1331–1336. discussion 1336.
Russo M, Malandrino P, Moleti M, et al. Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods. J Endocrinol Invest 2017; 40:1235–1241.
Chereau N, Giudicelli X, Pattou F, et al. Diffuse sclerosing variant of papillary thyroid carcinoma is associated with aggressive histopathological features and a poor outcome: results of a large multicentric study. J Clin Endocrinol Metab 2016; 101:4603–4610.
Malandrino P, Russo M, Regalbuto C, et al. Outcome of the diffuse sclerosing variant of papillary thyroid cancer: a meta-analysis. Thyroid 2016; 26:1285–1292.
Vuong HG, Kondo T, Pham TQ, et al. Prognostic significance of diffuse sclerosing variant papillary thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol 2017; 176:433–441.
Liu Z, Zeng W, Chen T, et al. A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis. Oncotarget 2017; 8:6222–6232.
Okuyucu K, Alagoz E, Arslan N, et al. Clinicopathologic features and prognostic factors of tall cell variant of papillary thyroid carcinoma: comparison with classic variant of papillary thyroid carcinoma. Nucl Med Commun 2015; 36:1021–1025.
National Cancer Database [Internet]. [cited 2018 Dec 13]. Available at: https://www.facs.org/quality-programs/cancer/ncdb .
Available at: www.facs.org/∼/media/files/quality programs/cancer/ncdb/puf data dictionary version puf 2015.ashx.pdf .
International Classification of Diseases for Oncology [Internet]. [cited 2018 Dec 11]. Available at: http://codes.iarc.fr/codegroup/2 .
NAACR ICD-0-3 Implementation Work Group. Guidelines for the ICD-O-3 Implementation [Internet]. [cited 2018 Dec 13]. Available at: https://www.naaccr.org/implementation-guidelines/ .
Wenig BM, Thompson LD, Adair CF, et al. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases. Cancer 1998; 82:740–753.
Akslen LA, Varhaug JE. Thyroid carcinoma with mixed tall-cell and columnar-cell features. Am J Clin Pathol 1990; 94:442–445.
Jiang C, Cheng T, Zheng X, et al. Clinical behaviors of rare variants of papillary thyroid carcinoma are associated with survival: a population-level analysis. Cancer Manag Res 2018; 10:465–472.
Geron Y, Benbassat C, Shteinshneider M, et al. Multifocality is not an independent prognostic factor in papillary thyroid cancer: a propensity score-matching analysis. Thyroid 2019; 29:513–522.
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–383.
Austin SR, Wong Y-N, Uzzo RG, et al. Why summary comorbidity measures such as the charlson comorbidity index and elixhauser score work. Med Care 2015; 53:e65–e72.
Cooper DS, Doherty GM, Haugen BR, et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167–1214.
Raue F, Frank-Raue K. Thyroid cancer: risk-stratified management and individualized therapy. Clin Cancer Res 2016; 22:5012–5021.
Kim BW, Yousman W, Wong WX, et al. Less is more: comparing the 2015 and 2009 american thyroid association guidelines for thyroid nodules and cancer. Thyroid 2016; 26:759–764.
Taskforce T, Cooper DS, Doherty GM, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16:109–142.
Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol 2005; 12:81–89.
Mendelsohn AH, Elashoff DA, Abemayor E, et al. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg 2010; 136:1055–1061.